State Budgetary Healthcare Institution of Moscow Region, Moscow Regional Research and Clinical Institute M.F.Vladimirskiy's
Key Words: chronic lymphocytic leukemia, flow cytometry, peripheral blood lymphocytes, minimal residual disease
Annotation: The article presents an analysis of the prognostic significance of tumor cell immunophenotypic markers clone in patients with B-cell chronic lymphocytic leukemia in the dynamics of ongoing immuno-chemotherapy - R-FC (rituximab, fludarabine, cyclophosphamide) in the evaluation of minimal residual disease. Expression of CD25 on B-lymphocytes can be a predictor of the quality of remission, progression or recurrence of the disease in patients with CLL.
Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, Lozanski G, Moreno C. et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic: Leukaemia, 2007, 21; 956-964.
Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab: Ann. Oncol 2003, 14; 520-535.
del Poeta G, del Principe MI, Irno Consalvo MA, Maurillo L, Buccisano F, Venditti A. et al. The addition of of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukaemia: Cancer, 2005, 104; 2743-2752.
Hallek V, Fisher K, Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial: Lancet, 2010, 376 (9747); 1164-74.
Pavlovsky C, Pavlovsky S, Pardo ML, Sapia S, MonrealM, Corrado C. et al. Therapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukaemia (CLL): Blood, 2006, 108; 4968.
Yarilin AA. Immunology. Moscow, GEOTAR-Media, 2010; 453.